How is it not good? From day 1 they have outlined two components to the market; US and Europe. $1B each. Why would they limit themselves to half the market for an FDA approved product? This would provide access and relationships to tap into the other half of the marketplace. Seems pretty straightforward Business 101 to me. On the other hand, they give themselves access to the other half of the market, in the unlikely event of FDA disapproval.
These actions seem to be in line with all other emerging business initiatives they have undertaken the last few months to be prepared to effectively get a product to market.
News 
Market Data 
Discover 
